---
title: "Akari Therapeutics shareholders approve key AGM resolutions"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291593554.md"
description: "Akari Therapeutics shareholders approved all key resolutions at its June 30, 2025 Annual General Meeting. Approved items included the election of directors, ratification of BDO USA as auditor, an increase in shares under the 2023 Plan, and compensation-related measures. This reflects strong shareholder support for the company's governance and strategy."
datetime: "2026-07-02T21:50:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291593554.md)
  - [en](https://longbridge.com/en/news/291593554.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291593554.md)
generator: "portal-rs"
---

# Akari Therapeutics shareholders approve key AGM resolutions

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Akari Therapeutics ( (AKTX) ) has issued an update.

On June 30, 2025, Akari Therapeutics held its Annual General Meeting where shareholders approved all matters presented, including the election of director nominees and the ratification of BDO USA, P.C. as the independent registered public accounting firm. The meeting also authorized an increase in the number of shares available under the 2023 Plan and approved compensation-related resolutions, reflecting strong shareholder support for the company’s strategic direction and governance.

The most recent analyst rating on (AKTX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.

**Spark’s Take on AKTX Stock**

According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.

Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.

To see Spark’s full report on AKTX stock, click here. 

**More about Akari Therapeutics**

**Average Trading Volume:** 24,113

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $33.47M

Learn more about AKTX stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [AKTX.US](https://longbridge.com/en/quote/AKTX.US.md)

## Related News & Research

- [Akari Therapeutics to present PH1 ADC payload platform at oncology and investor conferences](https://longbridge.com/en/news/298326364.md)
- [Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models](https://longbridge.com/en/news/296231720.md)
- [Exclusive: Big Four giant turns on its own auditor BDO over sloppy standards](https://longbridge.com/en/news/298558658.md)
- [Italian Sea Group amends Sept. 9 release, publishes BDO audit reports on 2025 accounts](https://longbridge.com/en/news/298595432.md)
- [Lee Enterprises replaces BDO with Grant Thornton as auditor after 2026 audit completion](https://longbridge.com/en/news/298498464.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**